Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

NCT06839456 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
High Risk Acute Lymphoblastic Leukemia
High Risk Acute Myeloid Leukemia
Relapse Leukemia
MDS (Myelodysplastic Syndrome)
Relapsed Non-Hodgkin Lymphoma
Acquired Aplastic Anemia
Inherited BMF Syndrome
Immunodeficiency
Primary Immune Regulatory Disorder
Hemoglobinopathies
Bone Marrow Failure
Inborn Errors of Metabolism
HLH

Interventions

DEVICE: Phase 1 Dose Level 1
DEVICE: Phase 1 Dose Level 2
DEVICE: Phase 1 Dose Level 3
DEVICE: Phase 2 Maximum Tolerated Dose determined in Phase 1
DEVICE: Phase 2 Established Dose from prior study, NCT03810196

Sponsor

Children's Hospital of Philadelphia